This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
Safety Profile and TolerabilityTRUMENBA has a safety profile established in 12 clinical trials and more than 16,000 individuals worldwide.1

The safety data demonstrated that TRUMENBA was generally well tolerated.1

The most common solicited adverse reactions in adolescents and young adults were1:

  • Fatigue (≥60%)
  • Headache (≥55%)
  • Pain at the injection site (≥85%)
  • Muscle pain (≥35%)
  • In clinical trials, adverse events occurred at lower rates with second and third doses of TRUMENBA compared with the first dose1

TRUMENBA is the only MenB vaccine with prefilled syringes not made with natural rubber latex.1

  • The tip cap and rubber plunger are not made with natural rubber latex
Real world experience

MenB strains expressing fHbp subfamilies A and B have caused disease outbreaks at colleges such as Providence College, Rutgers University, UC Santa Barbara, and University of Oregon.2-4

Not actual patients. For illustrative purposes only.

Use in Specific Populations1
  • Pregnancy: There are no adequate and well-controlled studies of TRUMENBA in pregnant women
  • Lactation: Available data are not sufficient to assess the effects of TRUMENBA on the breastfed infant or on milk production/excretion
  • Pediatric use: Safety and effectiveness have not been established in children <10 years of age
  • Geriatric use: Safety and effectiveness in adults >65 years of age have not been established
References:fHbp=factor H binding protein; MenB=serogroup B meningococcal disease.
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 1-800-666-7248.
References:1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. 2. Soeters HM, Dinitz-Sklar J, Kulkarni PA, et al. Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016. Emerg Infect Dis. 2017;23(5):867-869. 3. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607. 4. Data on file. Meningitis case outbreaks. Pfizer Inc., New York, NY. 5. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450. 6. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website.
http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed April 1, 2021. 7. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9. 8. Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118-1130. 9. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.
Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice
 Find out about TruSupportLoading
Why adolescents and young adults?Typical adolescent and young adult behaviors increase MenB risk.5-8 Learn more about MenBLoading
The science behind TRUMENBA

Only TRUMENBA targets both subfamilies, A and B, of fHbp.1,9

 See the scienceLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-TRU-USA-3203
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.